share_log
Moomoo 24/7 ·  Apr 3 08:07
VBI Vaccines Presents Early Tumor Response Data From Randomized Controlled Phase 2b Study Of VBI-1901 In Recurrent Glioblastoma; Early Data From Patients Eligible For Evaluation At Week 12 Show Two Observations Of Stable Disease, Indicating No Tumor Progression, In VBI-1901 Treatment Arm
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment